[The comparative efficacy of verapamil, nifedipine and propranolol in patients with IHD and an enhanced risk of a fatal outcome].
In a randomized controlled trial 329 postmyocardial infarction patients with high-grade ventricular extrasystoles were divided into 3 groups. Group 1 of 112 patients received calcium antagonists (verapamil, nifedipine, verapamil+nifedipine), group 2 of 100 patients received propranolol hydrochloride, group 3 consisted of 117 controls. The aim of the study was to elucidate the effect of the above drugs on sudden death and repeated nonfatal infarction risk. The mean follow-up duration made up 16 +/- 0.9, 16.8 +/- 1.1, 20.8 +/- 1.0 months for groups 1,2 and 3, respectively. 35 patients of the treatment groups turned out inappreciable because of early discontinuation of chemotherapy. Overall lethality for the groups 1, 2 and 3 reached 0.9%, 4% and 12% of patients, respectively. Most of lethal outcomes in the controls were sudden. Repeated nonfatal myocardial infarction arose less frequently in groups 1 and 2, but the difference was insignificant.
Mazur
N A
NA
Pavlova
T S
TS
Vasil'eva
N N
NN
Kul'ginskaia
I V
IV
D000328:Adult; D005117:Cardiac Complexes, Premature / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D017079:Exercise Tolerance / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D009543:Nifedipine / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*
D011433:Propranolol; D014700:Verapamil; D009543:Nifedipine